(6aR,9R)-7-methyl-5-(trifluoromethyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 英文名称: (6aR,9R)-7-methyl-5-(trifluoromethyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
• 化学式: C₁₇H₁₆F₃N₃O
• 分子量: 335.32
• InChiKey: UDVMBJOCIVJZRX-AMIZOPFISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  62.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] FLUOROERGOLINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE FLUOROERGOLINE ET LEURS UTILISATIONS
  申请人：MAP PHARMACEUTICALS INC

  公开号：WO2014100357A1

  公开（公告）日：2014-06-26

  Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.